Transcription factors in cell biology, surgery, and transplantation

Surgery

Volumn 128, Issue 1, 2000, Pages 1-5

  Hedin, Karen E ^a   Kaczynski, Joanna A ^a   Gibson, Mark R ^a   Urrutia, Raul ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TRANSCRIPTION FACTOR AP 1; TRANSFORMING GROWTH FACTOR BETA;

CYTOLOGY; ISCHEMIA; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; PROTEIN SYNTHESIS; REPERFUSION INJURY; REVIEW; TRANSCRIPTION REGULATION;

EID: 0033938027     PISSN: 00396060     EISSN: None     Source Type: Journal    
DOI: 10.1067/msy.2000.106426     Document Type: Article

References (28)

1. Cook PR. The organization of replication and transcription. Science 1999;284:1790-5.
2. Von Hippel PH. An integrated model of the transcription complex in elongation, termination, and editing. Science 1998;281:660-5.
3. Pain VM. Initiation of protein synthesis in eukaryotic cells. Eur J Biochem 1996;236:747-71.
4. Rothman JE, Wieland FT. Protein sorting by transport vesicles. Science 1996;272:227-34.
5. Wendland B, Emr SD, Riezman H. Protein traffic in the yeast endocytic and vacuolar protein sorting pathways. Curr Opin Cell Biol 1998;10:513-22.
6. Benson JD, Benson M, Howley PM, Struhl K. Association of distinct yeast Not2 functional domains with components of Gcn5 histone acetylase and Ccr4 transcriptional regulatory complexes. EMBO J 1998;17:6714-22.
7. Imhof A, Yang XJ, Ogryzko VV, Nakatani Y, Wolffe AP, Ge H. Acetylation of general transcription factors by histone acetyltransferases. Curr Biol 1997;7:689-92.
8. Schedl A, Hastie N. Multiple roles for the Wilms' tumour suppressor gene, WT1 in genitourinary development. Mol Cell Endocrinol 1998;140:65-9.
9. Nabel GJ. A transformed view of cyclosporine. Nature 1999;397:471-2.
10. Hojo M, Morimot T, Maluccio M, Asano T, Morimoto K, Lagman M, et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 1999;397:5304.
11. Letterio JJ, Roberts AB. Regulation of immune responses by TGF-beta. Annu Rev Immunol 1998;16:137-61.
12. Liu C, Adamson E, Mercola D. Transcription factor EGR-1 suppresses the growth and transformation of human HT-1080 fibrosarcoma cells by induction of transforming growth factor beta 1. Proc Natl Acad Sci U S A 1996; 93:11831-6.
13. Liu C, Cologero A, Ragona G, Adamson E, Mercola D. EGR-1, the reluctant suppression factor: EGF-1 is known to function in the regulation of growth, differentiation, and also has significant tumor suppressor activity and a mechanism involving the induction of TGF-beta1 is postulated to account for this suppressor activity. Crit Rev Oncol 1996; 7:101-25.
14. Liu C, Ya J, de Belle I, Huang RP, Adamson E, Mercola D. The transcription factor EGF-1 suppresses transformation of human fibrosarcoma HT1080 cells by coordinated induction of transforming growth factor-β1, fibronectin, and plasminogen activator inhibitor-1. J Biol Chem 1999;274:4400-11.
15. Yoo YD, Chiou CJ, Choi KS, Yi Y, Michelson S, Kim S, et al. The IE2 regulatory protein of human cytomegalovirus induces expression of the human transforming growth factor beta 1 gene through an Egr-1 binding site. J Virol 1996;70:7062-70.
16. Martin M, Vozenin MC, Gaul N, Crechet F, Pfarr CM, Lefaix JL. Coactivation of AP-1 activity and TGF-beta-1 gene expression in the stress response of normal skin cells to ionizing radiation. Oncogene 1997;15:981-9.
17. Thatikunta P, Raj GV, Kundu M, Khalili K, Amini S. The transcription factor E2F-1 modulates TGF-beta-1 RNA expression in glial cells. Oncogene 1997;14:2959-69.
18. Cosgaya JM, Perona, R, Aranda A. Retinoic acid induces secretion of transforming growth factors by PC12 pheochromocytoma cells. Oncogene 1997;14:579-87.
19. Ishibashi N, Weisbrot-Lefkowitz M, Reuhl K, Inouye M, Mirochnitchenko O. Modulation of chemokine expression during ischemia/reperfusion in transgenic mice overproducing human glutathione peroxidases. J Immunol 1999;163:5666-77.
20. Zwacka RM, Zhou W, Zhang Y, Darby CJ, Dudus L, Halldorson J, et al. Redox gene therapy for ischemia/reperfusion injury of the liver reduces AP-1 and NF-κB activation. Nat Med 1998;4:698-704.
21. Zwacka RM, Zhang Y, Zhou W, Halldorson J, Engelhardt JF. Ischemia/reperfusion injury in the liver of BALB/c mice activates AP-I and nuclear factor kappa B independently of IkappaB degradation. Hepatology 1998;28:1022-30.
22. Weisbrot-Lefkowitz M, Reuhl K, Perry B, Chan P, Inouye M, Mirochnitchenko O. Overexpression of human glutathione perioxidase protects transgenic mice against focal cerebral ischemia/reperfusion damage. Brain Res Mol Brain Res 1998;53:333-8.
23. Yoshida T, Watanabe M, Engelman DT, Engelman RM, Schley JA, Maulik N. Transgenic mice overexpressing glutathione peroxidase are resistant to myocardial ischemia/reperfusion injury. J Mol Cell Cardiol 1996;28: 1759-67.
24. Imbert V, Rupec RA, Livolsi A, Pahl HL, Traenckner EB, Mueller-Dieckmann C, et al. Tyrosine phosphorylation of I kappa B-alpha activates NF-kappa B without proteolytic degradation of I kappa B-alpha. Cell 1996;86:787-98.
25. Beraud C, Henzel WJ, Baeuerle PA. Involvement of regulatory and catalytic subunits of phosphoinositide 3-kinase in NF-kappa B activation. Proc Natl Acad Sci U S A 1999;96: 429-34.
26. Egan LJ, Mays DC, Huntoon CJ, Bell MP, Pike MG, Sandborn WJ, et al. Inhibition of interleukin-1-stimulated NF-kappaB RelA/p65 phosphorylation by mesalamine is accompanied by decreased transcriptional activity. J Biol Chem 1999;274:26448-53.
27. Nelson PJ, Krensky AM. Chemokines, lymphocytes and viruses: what goes around, comes around. Curr Opin Immunol 1998;10:265-70.
28. Nelson PJ, Krensky AM. Chemokines, lymphocytes, and viruses: what goes around, comes around. Curr Opin Immunol 1998;10:265-70.